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There is growing evidence that in last decade the incidence of long-term sequelae 
and perioperative complications in CHD infants undergone to OHS and CPB 
has considerably changed. The reasons of these astonishing results reside in the 
multidisciplinary approach to the disease, involving researchers not only appertaining 
to the same branch (obstetricians, neonatologists, neuroscientists, cardiologists, cardiac 
surgeons, biochemists etc.) but experts coming from different disciplines (medical 
doctor, biologists, molecular biologists, pharmacologists, bio-engineering, informatics, 
etc.). Nonetheless recent technological advances in prenatal diagnosis and interventions, 
in perioperative surgery and therapeutic strategies in NICU and PICU provided further 
effort [1,2]. This is especially true for: i) CHD perinatal screening, ii) delivery room 
management, iii) NICU and PICU admission and preparation to surgery, iv) new 
cardiac surgery techniques, v) careful CPB and post-operative management, and finally 
vi) a future standardized follow-up. Unfortunately, these promising results are, at this 
stage, still limited to developed countries. 
The aforementioned promising results do not let to provide a conclusive answer to the 
multidisciplinary team questions: 
i) which are the CHD cases at high risk for long-term brain injury due to OHS and CPB? 
ii) Which are the CHD cases at risk for perioperative multiorgan failure?
In light of this, it is widely known that the main issue to solve is CPB management that 
today constitutes a deliberate phase of hypoxia-ischemia as the cost to pay during OHS. 
Another unsolved problem resides in the “so-called” standard monitoring procedures 
that do not let to the multidisciplinary team to detect at early stage CHD infant’s cases 
at risk for perioperative morbidity and/or mortality. 
In the last decades, biochemical longitudinal monitoring of CHD infants in the 
perioperative period seemed to constitute a new tool able to let the multidisciplinary 
team reach their goal. In this regard, starting from pioneering research by Westaby et 
al. in 1996, after twenty years this issue is still controversial and a matter of debate [3]. 
On one side, previous promising observations in pediatric CHD infants showed that 
BM levels changed in CHD infants, during OHS and CPB, and correlated with the 
occurrence of adverse short-long term neurological sequelae [4]. On the other side, the 
exaggerated releasing of inflammatory cytokines due to HT, DHCA and the rewarming 
phase showed to affect the availability of some of them thus later abandoned [5-8]. 
This is especially true for NSE whilst S100B reliability has been recently re-confirmed 
[5-9]. However, no other trustable BM has been recently proposed and introduced in 
clinical guidelines [3,4]. Another explanation resides in the studies conducted in terms 
of design, sample size population, end-points as well as the lack of reference curve age-
dependent for the majority of the BM investigated. This latter issue has been highlight 
by recent FDA and EMA statements [10].
In the present thesis, we therefore aimed at providing further support to elucidate the 
diagnostic/predictive role of AcA and AM in the perioperative period.
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In Chapter 2 we provided an overview of the antenatal and perioperative mechanisms 
contributing to neurological impairments in critical CHD patients. CNS undergoes 
major morphological and microstructural changes during fetal life and the neonatal 
period. Accordingly, critical CHD survivors show primarily a large spectrum of global 
CNS dysmaturation due to chronic fetal hypoxia. In addition, perioperative hypoxia-
ischemia due to the CHD and the use of cardiopulmonary bypass or deep hypothermic 
circulatory arrest provide an additional hit to the neonatal CNS. Consequently, poor 
neurodevelopment including long-term neurocognitive and motor impairments 
are prevalent in critical CHD survivors, this despite advances in perioperative and 
intraoperative care. Innate patient factors, such as genetic syndromes and preterm 
birth, and postoperative complications play a larger role in neurological injury than 
perioperative factors. We stated that strategies to reduce the disability burden in critical 
CHD survivors are urgently needed. 
The review provides a framework for interpreting the mechanisms that may help 
understand the origin of the abnormal antenatal global CNS development and the 
superimposed perioperative global CNS hypoxia-ischemia in critical CHD.
In Chapter 3 an overview of the main BM (AcA, S100B, G-FAP, NSE, AM, oxidative 
stress) has been provided, focusing on the potential pros and cons to be overcome before 
any inclusion in clinical practice in agreement with FDA and EMA criteria [10,11]. 
At this stage only few BM are closer to being included in daily practice such as AcA 
and S100B. Conversely, although AM constitutes a potential reliable BM further 
investigations are needed. If we consider the CHD population the reliability of BM is 
still limited to S100B and AcA, but recent Literature data suggested that AM has great 
potential since it can play both role of vasoactive agent and neuro-marker [11-13].
Additional crucial points reside in the timing and in the reproducibility of the obtained 
results. The challenge for the multidisciplinary team resides to provide a panel of BM 
measurable from the same sample, in the shortest time, with the possibility of comparing 
results independently from different assessment methods, and finally at low costs for 
sample measurement. 
In Chapter 4 we investigated the reliability of AcA in the perioperative period as 
predictor of short-term adverse neurological outcome. For this purpose, we recruited 
45 CHD infants without preexisting neurological disorders who underwent OHS and 
CPB. Nine out of 45 CHD infants developed neurological injury at 7-d follow-up. AcA 
was measured in blood samples collected at different monitoring time-points. Results 
showed that AcA blood levels, significantly increased throughout the perioperative 
period peaking at the end of CPB. Notably, AcA levels were significantly increased in 
CHD infants developing brain injury up to 24 hours from surgery. At cut-off values 
chosen by the ROC curve analysis (before surgery, 0.94 μg/L; before CPB, 1.4 μg/L; 
at the end of CPB, 0.85 μg/L), AcA reached a sensitivity of 100% and a specificity of 
100%. 
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We therefore concluded that peri-operative AcA measurement provides useful 
information on the early detection of cases at risk for post-surgical neurological stress/
damage. 
Results on increased AcA levels in the perioperative period of CHD infant with good 
neurological outcome warrant further consideration. We are aware that the early 
increased AcA levels cannot be only expression of a peri-operative stress/damage, 
although at a sub-clinical stage. Other possibilities need to be explored such as: i) AcA 
neuro-protection and regenerative actions during and after OHS and CPB procedures. 
CPB procedure it-self, constituting the classic HIR event, may trigger the former role. 
The latter role may be interpreted as an activation of repair processes following CPB, ii) 
increased AcA due to changes in the brain blood barrier (BBB) permeability following 
CPB as for other BM [5-8]. To our knowledge, no conclusive results have been provided 
in pediatric patients: the fact that CBP in children affected BBB permeability, in a 
different modality when compared to adults, has to be taken into the due account (4-8). 
Thus, the possibility that part of the total amount of the protein detected in the systemic 
circulation could be BBB-dependent needs to be investigated, and iii) expression of 
CHD itself. In this regard, further studies aimed at evaluating AcA differences between 
cyanotic and non-cyanotic CHD are so justified. 
In Chapter 5 we investigated the reliability of AM and MCA Doppler velocimetry 
parameters in the perioperative period as predictors of adverse neurological outcome 
at 1-year of age. For this purpose, we recruited 50 CHD infants without preexisting 
neurological disorders who underwent OHS and CPB. Ten out 50 CHD infants 
developed neurological injury at 1-year follow-up. AM was measured in blood samples 
collected at different monitoring time-points.
Results showed that CHD infants who developed abnormal neurologic outcome had 
significantly higher MCA values and lower AM concentrations, than infants with 
normal neurologic outcome, at the end of CPB and after surgery. As single marker 
for predicting neurological abnormalities, AM (cut-off value: 17.4 ng/L) achieved a 
sensitivity of 100% and a specificity of 73.0%, and MCA (cut-off value: 1.8 ng/L) a 
sensitivity of 100% and a specificity of 56.8%.
We therefore concluded that peri-operative AM measurement provides useful information 
on the early detection of cases at risk for long-term post-surgical adverse neurological 
outcome. Of course, further multicenter investigations in a wider population are 
requested to confirm our observation. Similarly to Chapter 3, results on decreased AM 
levels in the peri-operative period of CHD infants with good neurological outcome 
warrant further consideration. Bearing in mind that AM can play both as vasoactive 
agent and as brain damage marker (acting as a cytokine) we can argue that the decreased 
AM levels during CPB cannot be only expression of a peri-operative stress/damage, 
although at a sub-clinical stage [5-8]. Other possibilities on the AM involvement of 
pathophysiological mechanisms CPB-related has to be taken into the due account 
such as: i) AM role in the control of cerebrovascular autoregulation system due to its 
local action. In this regard, it has been shown that AM release is bloodstream-specific 
Raul Abella inhoud v1.indd   133 27-8-2019   09:55:21
134
(systemic, pulmonary, cerebral, placental etc..) under different pathophysiological 
conditions such as pulmonary hypertension, fetal acute/chronic hypoxia, neonatal 
adaptation in the transitional phase (first 72-hours from birth) [5,14-18]. Thus, based 
on these findings it is tempting to infer that AM can play a role in BBB permeability 
and therefore constitutes a marker of BBB impairment due to stressing CPB phases. 
This issue is supported by previous observations in high risk newborns in whom AM has 
been shown to be involved in the cascade of HIR events leading to cerebral hemorrhage 
[15,16]; ii) AM release in an oxygen-dependent manner. Literature data reported that 
under conditions of chronic/acute hypoxia AM release in the systemic circulation, as 
vasodilation agent, is increased in order to maintain as much as possible the best total 
body oxygenation [14,18]. In the cooling CPB-phase due to low total body temperature 
the oxygen rate available is dramatically increased as shown at Chapters 3-5. Thus, the 
lower AM levels can be considered as a compensatory and/or protective mechanism to 
avoid hyper-oxygenation and consequent free radical over-production. The finding is 
corroborated by progressive increase in AM levels during the reperfusion (rewarming 
phase) up to 24-hours from surgery, and iii) AM release as expression of CHD itself. In 
this regard, further studies aimed at evaluating AM differences between cyanotic and 
non-cyanotic CHD are so justified.
Finally, In Chapter 6 we investigated AM role as predictor of LCOS in the perioperative 
period. We therefore conducted an observational study in 48 CHD infants of whom 
9 were complicated by intra-operative LCOS. The control group was composed of 39 
uncomplicated CHD infants. AM was measured in blood samples collected at different 
monitoring time-points.
Results showed that AM peri-operative concentrations decreased in CHD infants 
particularly in LCOS group at the end of CPB and of surgical procedure. Multivariable 
analysis performed to detect the best early predictor of LCOS among a series of standard 
clinical and laboratory monitoring parameters showed a significant correlation only 
with AM and cooling phase duration. AM at 27 pg/L cut-off achieved a sensitivity of 
100% and a specificity of 64.1% as the best single marker for the prediction of LCOS. 
We therefore concluded that AM can constitute a reliable parameter for LCOS prediction 
and multiorgan failure following LCOS. 
The present findings offered additional support to the usefulness of AM longitudinal 
assessment in the peri-operative period of CHD infants undergone to OHS and CPB. AM 
pattern of concentration during OHS was superimposable to that detected at Chapter 
5, thus supporting the notion of an AM involvement in the cerebral autoregulation 
system, in BBB permeability and in the vasoactive agent release inhibition due to hyper-
oxygen blood concentration and temperature (cooling, rewarming) CPB stress [5,14-
18]. However, before AM inclusion in the peri-operative routine some issues need to 
be addressed. First, the possibility to measure it at the bed-side providing at the surgical 
team the results as soon as possible; second, a reliable measurement assay and technique 
reproducible and at low cost; last but not least, the need of further investigations offering 
AM reference curves at the age under investigation.
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